BeyondSpring hires ex-Takeda and AstraZeneca veteran for pivotal period

2 August 2018

USA headquartered oncology specialist BeyondSpring (Nasdaq: BYSI) has named Richard Daly its chief operating officer to lead the transition to commercialization of the chemotherapy-induced neutropenia (CIN) drug plinabulin.

Mr Daly has more than 25 years of experience heading business and commercial operations for leading pharmaceutical and biotech companies, including as executive vice president at Japanese drugmaker Takeda Pharmaceuticals (TYO: 4502) in the USA, where he led commercial initiatives supporting expansion into oncology.

"The breadth of Richard’s insights and experience – in cancer therapeutics and specialty care – will be critical to setting the stage for commercial success with plinabulin"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK